Chronic Systemic Inflammatory Disease Research Articles

Increased Levels of C5a in Gingival Crevicular Fluid and Saliva of Patients with Periodontal Disease.

C5a is a powerful complement effector molecule that is considered to be an important proinflammatory mediator in several systemic chronic inflammatory diseases. However, its levels in periodontal diseases are yet to be assessed. We aimed to analyse the secretion of C5a in gingival crevicular fluid (GCF) and saliva of patients with periodontal disease. Twenty-eight patients diagnosed with stage 3–4 periodontitis and 16 periodontally healthy subjects participated in this study. GCF was collected from sites with the deepest probing depth of each patient, and volume was measured using a Periotron 8000®. One mL of unstimulated saliva was also collected. Samples were analysed using a commercially available ELISA kit. The data were analysed using the Mann–Whitney U test, Pearson’s bivariate testing, and receiver operating characteristic curve. C5a was present in GCF from patients with periodontitis (1.06 ± 0.25 ng/mL) whilst it was undetected in controls. Saliva concentration was also significantly higher in periodontitis (1.82 ± 2.31 ng/mL) than controls (0.60 ± 0.72 ng/mL, p = 0.006). C5a levels were more pronounced in periodontitis in both oral fluids assessed by the present pilot study. These results suggest that the more pronounced levels of C5a in oral fluids from periodontitis patients indicate a potential role of this molecule in this disease pathogenesis, deserving to be better explored in subsequent studies.

Fibrinogen-Like Protein 1 as a Novel Biomarker of Psoriasis Severity

BackgroundPsoriasis is an immune-mediated chronic systemic inflammatory skin disease whose diagnosis and severity assessment pose challenges for clinicians worldwide. The use of serum biomarkers facilitates the early diagnosis and treatment of psoriasis.MethodsThis case–control study compared tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-17, IL-10, and fibrinogen-like protein 1 (FGL1) levels of 139 untreated psoriasis patients and 140 healthy controls. Serum samples were collected, and enzyme-linked immunosorbent assays were performed to quantify their levels. Subgroups were analyzed according to abnormal lipid metabolism status.ResultsCompared to controls, patients with psoriasis exhibited lower concentrations of serum TNF-α, IL-17, and FGL1 (P < 0.05). A correlation analysis showed that FGL1 was inversely correlated with high-density lipoprotein cholesterol and IL-17 in the psoriatic state. Stepwise multiple regression analysis revealed that FGL1 and total cholesterol were the independent determinants of Psoriasis Area and Severity Index (PASI) score in psoriasis patients. The area under the receiver operating characteristic curve of FGL1 assessing moderate-to-severe psoriasis and mild psoriasis was 0.70, while the area under the curve (AUC) assessing severe psoriasis and mild-to-moderate psoriasis was 0.67, better than that of IL-17. In addition, FGL1, but not IL-17, was able to identify psoriasis with abnormal lipid metabolism to a certain extent (AUC = 0.60).ConclusionIn conclusion, serum FGL1 may be a promising biomarker for diagnosing and staging psoriasis. It may also be involved in its progression and comorbid abnormal lipid metabolism.

Glucose metabolism in systemic juvenile idiopathic arthritis

BackgroundSystemic juvenile idiopathic arthritis (SJIA) is a chronic systemic inflammatory disease in children. Overproduction of inflammatory cytokines in SJIA resembles that in adult onset Still disease. Chronic inflammation causes insulin resistance and consequently leading to abnormal glucose metabolism. Adults with rheumatoid arthritis (RA) have increased risks of abnormal glucose metabolism and diabetes. To date, glucose metabolism in patients with SJIA has not been elucidated.MethodsPatients with SJIA aged 4–25 years were recruited. All patients underwent an oral glucose tolerance test (OGTT). Indices of insulin sensitivity [homeostasis model assessment for insulin resistance (HOMA-IR) and whole-body insulin sensitivity index (WBISI)] and β-cell function [insulinogenic index (IGI) and disposition index (DI)] were calculated. Obese children with normoglycemia who underwent the OGTT were served as a control group.ResultsA total of 39 patients with SJIA, aged 4–25 years, median (IQR) BMI SDS was 0.1 (-0.5 to 1.7). Patients were divided into 2 groups, overweight/obese (OW/OB) (n = 11) and lean (n = 28). Only one obese patient had prediabetes and none had diabetes. In comparison with sex- and age-matched OW/OB controls (n = 33), OW/OB patients with SJIA had higher insulin resistance [median (IQR) HOMA-IR: 2.6 (2.1–3.3) vs 1.5 (0.8–2.0), p = 0.001], lower insulin sensitivity [median (IQR) WBISI: 3.7 (2.7–5.9) vs 5.4 (4.5–8.7), p = 0.024], and higher insulin secretion [median (IQR) IGI: 2.5 (2.0–3.5) vs 1.0 (0.8–1.9), p = 0.001]. In lean patients with SJIA, insulin sensitivity indices seemed to be comparable with those of lean controls.ConclusionsOverweight/obese children with SJIA seemed to have increased insulin resistance and thus may have an increased risk for developing diabetes.

BAG3 Alleviates Atherosclerosis by Inhibiting Endothelial-to-Mesenchymal Transition via Autophagy Activation.

Atherosclerosis is a chronic systemic inflammatory disease that causes severe cardiovascular events. B cell lymphoma 2-associated athanogene (BAG3) was proven to participate in the regulation of tumor angiogenesis, neurodegenerative diseases, and cardiac diseases, but its role in atherosclerosis remains unclear. Here, we aim to investigate the role of BAG3 in atherosclerosis and elucidate the potential molecular mechanism. In this study, ApoE−/− mice were given a tail-vein injection of BAG3-overexpressing lentivirus and fed a 12-week high-fat diet (HFD) to investigate the role of BAG3 in atherosclerosis. The overexpression of BAG3 reduced plaque areas and improved atherosclerosis in ApoE−/− mice. Our research proves that BAG3 promotes autophagy in vitro, contributing to the suppression of EndMT in human umbilical vein endothelial cells (HUVECs). Mechanically, autophagy activation is mediated by BAG3 via the interaction between BAG3 and its chaperones HSP70 and HSPB8. In conclusion, BAG3 facilitates autophagy activation via the formation of the chaperone-assisted selective autophagy (CASA) complex interacting with HSP70 and HSPB8, leading to the inhibition of EndMT during the progression of atherosclerosis and indicating that BAG3 is a potential therapeutic target for atherosclerosis.

807 Hidradenitis suppurativa type 17 T-cell transcriptome is different from psoriasis

Hidradenitis suppurativa (HS) is a chronic systemic and cutaneous inflammatory disease driven by a multitude of immune cells. Recent studies have demonstrated that IL17A/IL17F isoform signal blocking psoriasis (PsO) drugs can effectively treat HS, suggesting Type 17 T-cells (T17 cells) play a critical role in HS lesion development. We sought to define and compare the single-cell transcriptomes of HS T17 cells to PsO T17 cells and further compare their respective ligand receptor interactions with neighboring immune cell subsets using single cell transcriptome data.

STUDI PENGETAHUAN DAN SIKAP TERHADAP PENGGUNAAN TUMBUHAN OBAT UNTUK MENGOBATI REMATIK PADA MASYARAKAT KOTA BAUBAU SULAWESI TENGGARA

The use of plants as medicine or traditional ingredients has been carried out since ancient times by people in Indonesia, either as an effort to cure or prevent a disease. One of the diseases that is often found in the community is rheumatism. Rheumatism is a chronic systemic inflammatory disease that attacks the joints, especially the synovial joints. This study aims to identify and obtain an overview of knowledge and attitudes towards the use of medicinal plants to treat rheumatism in people in the city of Baubau, Southeast Sulawesi. This research uses descriptive non- experimental method. In this study, a questionnaire was used as an instrument to collect data. The number of samples in this study were 90 respondents with a sampling technique, namely proposive sampling. Based on the research that has been done, it is found that 65.6% have good knowledge and 57.8% of the respondents show a positive attitude. Thus it can be concluded that the people in Baubau City, Southeast Sulawesi have good knowledge and show a positive attitude towards the use of medicinal plants to treat rheumatism.

Iatrogenic Fracture in a Patient of Ankylosing Spondylitis Planned for Surgical Correction of Chin-on-Chest Deformity

Ankylosing spondylitis (AS) is a progressive systemic chronic inflammatory rheumatic disease that causes arthritis of spine and sacroiliac joints and finally results in contracture or bony fusion of these joints. The ankylosed spine has increased propensity to fracture due to rigidity, long lever arms, and osteoporosis. However, iatrogenic fracture occurring in AS patients with chin-on-chest deformity during positioning has not been reported. A 46-year-old male, known case of AS, presented with progressive deformity of neck for the last 6 months due to C5 fracture with C4/5 dislocation. He had chin-on-chest deformity with chin-brow vertical angle of 106o with spastic tetraparesis (mJOA score 6, Nurick grade-3). The patient was put on sustained halo-gravity traction by gradually increasing the weight up to 30 lbs for 4 weeks and then was planned for deformity correction. After intubation and application of same traction, we found anterior wedge opening and fracture through C6/7 disc space. His neurology was found to be same as in the preoperative state on neural monitoring and wake up test. Front and back instrumented fusion was done with anterior bone grafting. Postoperatively, he was maintained on halo-vest immobilization for three months. By the end of first year, the fracture had united well and he was mobilizing well with mJOA score 13 and Nurick grade-1. AS patients are at higher risk of fracture and need utmost care while positioning during surgery. Traction or any corrective maneuver must be done carefully.

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis.

Background:Psoriasis is a chronic systemic inflammatory disease, and hyperuricemia is a common comorbidity in patients with psoriasis. However, there are limited reports on the relationship between serum uric acid levels and biological treatment efficacy. The purposes of this study were to compare the differences in serum uric acid levels between patients with psoriasis and healthy controls and analyze the risk of hyperuricemia.Methods:A total of 196 patients with psoriasis and 191 age- and sex-matched healthy controls were enrolled in this retrospective cohort study. One hundred and twenty-seven patients with severe psoriasis were treated with biologics. Sixty-eight patients received adalimumab, and 59 patients received secukinumab. Serum uric acid levels were measured at baseline, week 24, and week 48 of treatment.Results:Patients with psoriasis had higher serum uric acid levels than healthy controls (6.4 ± 1.7 mg/dL vs. 5.7 ± 1.5 mg/dL, P < 0.001). Hyperuricemia was found in 33.7% (66/196) of patients with psoriasis, which was significantly higher than that in healthy controls (13.1% [25/191], P < 0.001). Serum uric acid levels and hyperuricemia were not related to the severity of psoriasis (P > 0.05). No significant changes in serum uric acid levels and hyperuricemia were observed following adalimumab treatment (P > 0.05). The serum uric acid level in patients treated with secukinumab was 6.7 ± 1.6 mg/dL at week 24, which was not statistically different from that at baseline (6.6 ± 1.4 mg/dL, P = 0.885). Serum uric acid levels were significantly decreased at week 48 (6.3 ± 1.5 mg/dL vs. 6.6 ± 1.4 mg/dL, P = 0.007) in patients treated with secukinumab. Secukinumab had no significant effect on hyperuricemia either (P > 0.05).Conclusions:The serum uric acid levels and prevalence of hyperuricemia in patients with psoriasis were significantly higher than those in healthy controls. Secukinumab treatment for 48 weeks successfully decreased serum uric acid levels in patients with psoriasis, whereas adalimumab had no significant effect on serum uric acid levels.

Molecular Detection of Porphyromonas gingivalis in COVID-19 Patients

Background:SARS-CoV-2 infection has caused a global pandemic that continues to negatively impact human health. A large group of microbial domains including bacteria co-evolved and interacted in complex molecular pathogenesis along with SARS-CoV-2. Evidence suggests that periodontal disease bacteria are involved in COVID-19, and are associated with chronic inflammatory systemic diseases. This study was performed to investigate the association between bacterial loads of Porphyromonas gingivalis and pathogenesis of SARS-CoV-2 infection. Fifty patients with confirmed COVID-19 by reverse transcriptase-polymerase chain reaction, their age ranges between 20-76 years, and 35 healthy volunteers (matched accordingly with age and sex to the patients) participated in this case control study. Oral hygiene status was determined by the simplified oral hygiene index. Blood and saliva samples were obtained from patients and controls, Porphyromonas gingivalis quantification from extracted DNA of blood and saliva samples performed by means of real-time polymerase chain reaction. The present result revealed that the quantity of salivary Porphyromonas gingivalis was significantly higher (p=0.003) in the patients’ group than in the controls group, while there was no significant difference in the number of bacteria in the blood samples between the two groups. Moreover, the number of bacteria in severe cases was higher than that in moderate and mild with no significant differences, and there was a significant increase in the number of bacteria among patients with poor oral hygiene compared to patients with good oral hygiene. This study demonstrated that the high level of salivary Porphyromonas gingivalis in patients increases in number with disease severity, which may indicate that bacterial infections contribute to the spread of the disease.

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.

Psoriasis is a chronic systemic inflammatory disease. Due to systemic inflammation, it is associated with many comorbidities. Among them, cardiovascular diseases represent the most common causes of morbidity and mortality in this population. Therefore, physicians treating patients with psoriasis should keep in mind that, as important as the treatment of psoriasis, awareness of cardiovascular risk deserves additional attention. Thus, in parallel with psoriasis treatment, a cardiovascular risk assessment must also be performed and addressed accordingly. In addition to encouraging non-pharmacologic strategies for a healthy lifestyle, physicians should be familiar with different pharmacologic options that can target psoriasis and reduce cardiovascular risk. In the present article, we present the pathophysiological mechanisms of the psoriasis and cardiometabolic interplay, our view on the interaction of psoriasis and cardiovascular disease, review the atherosclerotic effect of therapeutic options used in psoriasis, and vice versa, i.e., what the effect of medications used in the prevention of atherosclerosis could be on psoriasis.

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.

Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab in large sample population was unknown. The current study was to evaluate the secukinumab-assocaited adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports in the FAERS from the first quarter of 2015 (FDA approval of secukinumab) to the third quarter of 2021 were collected and analyzed. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms, were employed in data mining to quantify the signals of secukinumab-related AEs. Results: A total of 89,228 reports of secukinumab as the “primary suspected (PS)” and 254,886 AEs induced by secukinumab were identified. Secukinumab-induced AE occurrence targeted 27 system organ classes (SOCs). A total of 257 signals of secukinumab-induced AEs in 19 SOCs were detected after conforming to the four algorithms simultaneously. Common significant signals of infections, respiratory disorders, skin and subcutaneous tissue disorders, immune system disorders, and ear and labyrinth disorders have emerged. Unexpected significant AEs such as injection site pain, vessel puncture site haemorrhage, arthralgia, hypokinesia, Bell’s palsy, parotid gland enlargement, and stress might also occur. The median onset time of secukinumab-associated AEs was 56 days (interquartile range [IQR] 5–214 days), and most of the onsets occurred within the first 1, 2, 3, and 4 months after initiation of secukinumab. Conclusion: Our study found potential new AE signals and provided a broader understanding of secukinumab’s safety profiles, supporting its rational use in chronic systemic inflammatory diseases.

Annoying Psoriasis and Atopic Dermatitis: A Narrative Review.

Skin is an important organ that mainly functions as a barrier. Skin diseases can damage a person’s self-confidence and reduce their willingness to socialize, as well as their social behavior and willingness. When the skin appearance is abnormal, in addition to affecting the quality of life, it often leads to personal, social, and psychological dysfunction and even induces depression. Psoriasis and atopic dermatitis are common chronic skin diseases. Their prevalence in the world is 3–10%, and there is an increasing trend year by year. These congenital or acquired factors cause the dysfunction of the immune system and then destroy the barrier function of the skin. Because these patients are flooded with a variety of inflammatory mediators, this causes skin cells to be in chronic inflammation. Therefore, psoriasis and atopic dermatitis are also considered systemic chronic inflammatory diseases. In the healthcare systems of developed countries, it is unavoidable to spend high costs to relieve symptoms of psoriasis and atopic dermatitis patients, because psoriasis and atopic dermatitis have a great influence on individuals and society. Giving a lot of attention and developing effective treatment methods are the topics that the medical community must work on together. Therefore, we used a narrative review manuscript to discuss pathogenesis, clinical classification, incidence, and treatment options, including topical medication, systemic therapeutics, immunosuppressive medication for psoriasis, and atopic dermatitis, as well as also comparing the differences between these two diseases. We look forward to providing readers with comprehensive information on psoriasis and atopic dermatitis through this review article.

Penurunan Skala Nyeri Rheumatoid Arthritis dengan Terapi Simple Reminiscance

Background: Rheumatoid arthritis is a chronic systemic inflammatory disease with the main manifestations of progressive polyarthritis and involving all organs of the body. The negative impact of this disease has a significant effect on the ability to carry out activities, both in terms of work or in household tasks, resulting in an increase in socio-economic costs, and can impact the quality of life and life expectancy of the sufferer. Methods: This research is a type of quasy experiment research with one group pre and post test design. Results: The highest level of pain before being given Simple Reminiscence therapy intervention was moderate pain level (71.4%) and after being given intervention the level of pain felt by respondents was mild pain level (100%). Based on the results of the Paired Test, it was obtained that p-value = 0.000 which means significant, so it can be concluded that there is an effect of providing Simple Reminiscence therapy intervention on reducing the level of rheumatoid arthritis pain in the elderly at the Panti Sosial Tresna Werdha., Bengkulu City.Keywords: pain, rheumatoid arthritis, simple reminiscence therapy

Rheumatoid Arthritis, Its Diagnostic Approach and How to treat it

Introduction. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by symmetrical erosive polyarthritis leading to progressive disability. It is more common in women, with a 3:1 ratio. Environmental risk factors are smoking, exposure to silica and textile dust. Materials and methods. Fifteen articles and three books on rheumatoid arthritis were chosen to identify the most accurate diagnostic methods and the most effective and innovative treatments. Discussion. Related autoantibodies, such as rheumatoid factors, anti-citrullinated antibodies and anti- caramylated antibodies can be found in serum long before the disease develops. The interaction between genetic and environmental factors causes a breakdown of immune tolerance and triggers systemic autoimmunity. It has been shown that the lungs, oral mucosa, and gastrointestinal tract are initial sites where the immune system can become activated and produce RA. Different imaging techniques are available for diagnosis: plain radiography, Doppler ultrasound, and magnetic resonance imaging. Doppler ultrasound was found to be more sensitive in identifying minimal synovitis and more sensitive than plain radiography in detecting joint erosions. As pharmacological treatment, it has been concluded that the first-line drug is methotrexate, as it relieves signs and symptoms, improves physical function, and prevents or slows the progression of joint damage. We also observed that NSAIDs help in the inflammatory and symptomatic control of RA. Conclusion. The quality of life of affected patients has been maintained thanks to the early detection of the disease, since there are several treatments (physical therapies, aerobic exercises, medications, etc.), which help to stop the evolution of this disease and thus allow the patient to lead a daily life.

Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis.

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease and its treatment is an urgent problem of rheumatology. Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 and is one of the few promising drugs for RA therapy. One-hundred-and-twenty-five DNA samples from Russian patients with RA, treated with olokizumab, were genotyped with an NGS panel containing 60 single nucleotide polymorphisms (SNPs) and the whole coding sequences of IL6, IL6R, TNFRSF1A, CTLA4, IL10, IL23R, and PADI4; and by RT-PCR for HLA-DRB1 and HLA-B. Associations of polymorphic variants with olokizumab efficacy according to the scores ACR20, ACR50, and DAS28-CRP were determined. We analyzed the obtained data by using logistic regression, ROC curves, and multivariate ANOVA. A high predictive value of the response to olokizumab therapy at 24 weeks was found for the combination of HLA-DRB1*04 and HLA-B*27 alleles with SNPs located in non-HLA genes (IL1B, IL17A, PADI4, DHODH, GLCCI1, IL23R, and TNFAIP3), and clinical characteristics (age, RA duration, and intensity) according to ACR20. Thus, the comprehensive assessment of polymorphic variants of HLA and non-HLA genes considering population characteristics in combination with clinical parameters allows for the elaboration of an RA prognostic panel.

PERIPHERAL BLOOD CELL SUBSET EPIGENOTYPING OF KNEE OSTEOARTHRITIS PAIN, RADIOGRAPHIC, AND DUAL PROGRESSORS VIA DECONVOLUTION USING TENSOR COMPOSITION ANALYSIS: DATA AND BIOSPECIMENS FROM THE OSTEOARTHRITIS INITIATIVE

Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes, and has been described as a chronic systemic inflammatory disease. Substantial epigenetic changes have been identified in OA joints, but less is known about extraarticular tissues. In this study, we apply tensor composition analysis to extract cell-type-specific DNA methylation data from baseline buffy coat DNA samples in a subgroup of osteoarthritis initiative (OAI) patients who exhibited future pain, radiographic, or pain+radiographic progression compared to nonprogressor controls.

Сложности оценки поражений сердца и стратификации кардиоваскулярного риска у больных с ревматоидным артритом

.ru Abstract Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of the connective tissue with a progressive lesion of predominantly peripheral joints with frequent extra-articular manifestations, among which heart damage, according to autopsy data, is observed in up to 60% of cases. At the same time, clinical changes in the heart, as a rule, are minimal and rarely come to the fore in the overall picture of the underlying disease. This review considers lesions of the membranes of the heart, pathology of the coronary arteries, secondary amyloidosis of the heart in RA. With damage to the joints, when physical activity is noticeably reduced, cardiac pathology is often masked, which requires a more careful and thorough examination of the patient from the doctor. In addition, the doctor will receive information about the stratification of cardiovascular risk in RA, learn to identify groups of patients with RA who are predisposed to the development of cardiovascular complications, and be able to develop a set of preventive and therapeutic measures aimed at reducing the risk individually for each patient; to create a system of dynamic control and monitoring of the development of cardiovascular pathology in this category of patients and purposefully treat comorbid patients.

Role of Interleukin-17A in the Pathomechanisms of Periodontitis and Related Systemic Chronic Inflammatory Diseases.

Periodontitis is a chronic inflammatory and destructive disease caused by periodontal microbial infection and mediated by host immune response. As the main cause of loosening and loss of teeth in adults, it is considered to be one of the most common and serious oral diseases in the world. The co-existence of periodontitis and systemic chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, diabetes and so on is very common. It has been found that interleukin-17A (IL-17A) secreted by various innate and adaptive immune cells can activate a series of inflammatory cascade reactions, which mediates the occurrence and development of periodontitis and related systemic chronic inflammatory diseases. In this work, we review the role of IL-17A in the pathomechanisms of periodontitis and related systemic chronic inflammatory diseases, and briefly discuss the therapeutic potential of cytokine targeted agents that modulate the IL-17A signaling. A deep understanding of the possible molecular mechanisms in the relationship between periodontitis and systemic diseases will help dentists and physicians update their clinical diagnosis and treatment ideas.

Evaluation of cardiovascular autonomic function in patients with rheumatoid arthritis

Rheumatoid arthritis (RA) is a type of inflammatory arthritis that affects people all over the world. RA is a chronic systemic inflammatory autoimmune disease. It primarily affects the joints and is frequently accompanied by extra-articular symptoms such as rheumatoid nodules, neuropathy, and normochromic normocytic anaemia. Objectives- The aim of this study was to evaluate cardiac autonomic function in patients with rheumatoid arthritis and compare with healthy individuals. An observational, cross-sectional study was done between 50 having RA &amp; 50 normal healthy subjects not on any medication, on both males &amp; females between the age group of 30-60 years. Evaluation of autonomic nervous system was done with the help of non-invasive tests. Parasympathetic system was assessed by heart rate response to standing &amp; heart rate response to lying down position. Sympathetic system was assessed by blood pressure response to standing, BP response to Valsalva Maneuverer &amp; BP response to sustained hand grip. In individuals with Rheumatoid Arthritis, the diastolic blood pressure in standing position was significantly lower(p&amp;#60;0.01) than control group. Other parameters showed non- significant changes in RA group compared to control group. Discussion- study confirmed autonomic dysfunction occurs in patient with rheumatoid arthritis. Therefore, autonomic function may be the part of routine clinical examination in RA to reduce the cardiovascular autonomic morbidity Cardiovascular autonomic function tests in daily clinical examination helpful in early detection of autonomic dysfunction in rheumatoid arthritis.

MiR-185-5p Regulates Inflammation and Phagocytosis through CDC42/JNK Pathway in Macrophages.

Macrophage activation is an essential component of systemic chronic inflammation and chronic inflammatory diseases. Emerging evidence implicates miR-185-5p in chronic inflammation diseases. However, the regulatory role of miR-185-5p in macrophage pro-inflammatory activation has not been studied previously. Here, we identified that miR-185-5p was one of the top genes and effectively downregulated in two macrophage miRNA expression datasets from GEO. Under LPS stress, miR-185-5p overexpression reduced pro-inflammatory cytokine expression, suppressed phagocytosis in RAW264.7 macrophage. miR-185-5p inhibitors augmented pro-inflammatory effects of LPS in macrophage. Mechanically, miR-185-5p sponged and negatively regulated the protein expression of CDC42. Ablation of CDC42 with selective CDC42 inhibitor CASIN reversed the pro-inflammatory effect of miR-185-5p inhibitors through inhibiting MAPK/JNK pathways. Collectively, these data demonstrate that miR-185-5p exhibited anti-inflammatory functions in LPS-induced RAW264.7 macrophages at least partially through CDC42/JNK pathways. Our findings yield insights into the understanding of miR-185-5p-regulated network in macrophages inflammation, which is beneficial for exploring miRNA-protein interaction in atherosclerotic inflammation.